Atazanavir Sulfate Gets a Nod at the 6th International AIDS Society Conference


IAS2011Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir sulfate is an azapeptide inhibitor of the HIV-1 protease. A staggering 1.1 million Americans are living with HIV, therefore the treatment needs for these patients are immense. As a relatively new, once-daily protease inhibitor, atazanavir was approved for HIV treatment by the U.S. Food and Drug Administration (FDA) in 2003.  Additionally, The U.S. Department of Health and Human Services treatment guidelines currently list Norvir (ritonavir)-boosted Reyataz plus Truvada (emtricitabine/tenofovir) as the preferred antiretroviral regimen for HIV-positive adults who are beginning treatment for the first time.

Atazanavir SulfateAvailable as capsules for oral administration in dosages of 100 milligrams, 150 milligrams, 200 milligrams and 300 milligrams,  atazanavir sulfate has proven in studies to be efficacious. In fact, a recent review of a simplified two-drug regimen using Norvir-boosted Reyataz (atazanavir) revealed that this option appeared to be as effective as three-drug regimens in patients with well-controlled HIV infection. This news was exciting for participants when it was disseminated at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. A simpler and easier treatment plan bodes well for physicians and patients alike, as a less complicated  drug regimen means better patient adherence and less adverse effects. Current side effects of atazanavir sulfate can include  nausea, vomiting, diarrhea, stomach pain, changes in the shape or location of body fat, dizziness and a mild skin rash.

In the United States an estimated 56,300 people will become infected with HIV this year, and according to the CDC 1 in 4 individuals currently have HIV and don’t know it.  Worldwide there are over 33 million people living with HIV.  These alarming statistics indicate the urgent need for research and development of generic options of atazanavir sulfate, and LGM Pharma can provide this API. LGM Pharma is a leading and reputable provider of API atazanavir, as well as other antiretroviral APIs, and offers clients complete support throughout the research and development process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: